KR20220009954A - 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 - Google Patents

신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 Download PDF

Info

Publication number
KR20220009954A
KR20220009954A KR1020217037272A KR20217037272A KR20220009954A KR 20220009954 A KR20220009954 A KR 20220009954A KR 1020217037272 A KR1020217037272 A KR 1020217037272A KR 20217037272 A KR20217037272 A KR 20217037272A KR 20220009954 A KR20220009954 A KR 20220009954A
Authority
KR
South Korea
Prior art keywords
subject
psilocybin
disorder
sleep
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217037272A
Other languages
English (en)
Korean (ko)
Inventor
데릭 존 론데스브로
크리스토퍼 브라운
줄리안 스캇 노턴
질리언 무어
헤만트 캐쉬내쓰 파틸
데이비드 이 니콜스
메건 크롤
한스 에이크 에릭손
조지 골드스미스
몰리 타비사 히키
숀 헐리
예카테리나 말리에프스카이아
린지 마우드
드러몬드 이웬 조 맥컬로치
로리 엠마 메드허스트
네이선 폴센
아슬리한 셀림베이요글루
아나이스 소울라
아만다 탄 슈시앙
마농 세실 엘리자베스 베라아트
토비아스 패트릭 웰런
라스 크리스티안 와일드
스티븐 라이트
Original Assignee
컴퍼스 패쓰파인더 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 컴퍼스 패쓰파인더 리미티드 filed Critical 컴퍼스 패쓰파인더 리미티드
Publication of KR20220009954A publication Critical patent/KR20220009954A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
KR1020217037272A 2019-04-17 2020-04-17 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 Pending KR20220009954A (ko)

Applications Claiming Priority (41)

Application Number Priority Date Filing Date Title
US201962835485P 2019-04-17 2019-04-17
US201962835482P 2019-04-17 2019-04-17
US201962835450P 2019-04-17 2019-04-17
US201962835472P 2019-04-17 2019-04-17
US201962835474P 2019-04-17 2019-04-17
US201962835484P 2019-04-17 2019-04-17
US201962835477P 2019-04-17 2019-04-17
US201962835480P 2019-04-17 2019-04-17
US201962835458P 2019-04-17 2019-04-17
US201962835465P 2019-04-17 2019-04-17
US201962835479P 2019-04-17 2019-04-17
US201962835481P 2019-04-17 2019-04-17
US201962835476P 2019-04-17 2019-04-17
US201962835464P 2019-04-17 2019-04-17
US201962835460P 2019-04-17 2019-04-17
US201962835478P 2019-04-17 2019-04-17
US201962835449P 2019-04-17 2019-04-17
US62/835,464 2019-04-17
US62/835,479 2019-04-17
US62/835,481 2019-04-17
US62/835,485 2019-04-17
US62/835,478 2019-04-17
US62/835,484 2019-04-17
US62/835,480 2019-04-17
US62/835,465 2019-04-17
US62/835,482 2019-04-17
US62/835,472 2019-04-17
US62/835,477 2019-04-17
US62/835,458 2019-04-17
US62/835,476 2019-04-17
US62/835,449 2019-04-17
US62/835,450 2019-04-17
US62/835,474 2019-04-17
US62/835,460 2019-04-17
US201962893110P 2019-08-28 2019-08-28
US62/893,110 2019-08-28
US201962893611P 2019-08-29 2019-08-29
US62/893,611 2019-08-29
US201962946159P 2019-12-10 2019-12-10
US62/946,159 2019-12-10
PCT/IB2020/053684 WO2020212948A1 (en) 2019-04-17 2020-04-17 Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

Publications (1)

Publication Number Publication Date
KR20220009954A true KR20220009954A (ko) 2022-01-25

Family

ID=70465167

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020217037272A Pending KR20220009954A (ko) 2019-04-17 2020-04-17 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
KR1020217037273A Pending KR20220009955A (ko) 2019-04-17 2020-04-17 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료
KR1020217037271A Pending KR20220008824A (ko) 2019-04-17 2020-04-17 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217037273A Pending KR20220009955A (ko) 2019-04-17 2020-04-17 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료
KR1020217037271A Pending KR20220008824A (ko) 2019-04-17 2020-04-17 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법

Country Status (9)

Country Link
US (8) US12433904B2 (https=)
EP (3) EP3955936A1 (https=)
JP (6) JP2022529781A (https=)
KR (3) KR20220009954A (https=)
CN (3) CN113993523A (https=)
AU (3) AU2020257625B2 (https=)
CA (3) CA3138100A1 (https=)
TW (1) TW202103699A (https=)
WO (3) WO2020212948A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210121125A1 (en) * 2018-07-13 2021-04-29 Pst Inc. Apparatus for estimating mental/neurological disease

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11701348B1 (en) 2016-07-23 2023-07-18 Turtle Bear Holdings, Llc Psilocybin compositions
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US20230368919A1 (en) * 2017-11-30 2023-11-16 Viewmind, Inc. Method for identifying specific alterations in subjects with defined diseases analyzing oculomotor patterns when using specific visual stimuli, where a specific drug or treatment would enhance visual processing, cognitive performance and related brain activities
EP4219498A1 (en) * 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
WO2020237043A1 (en) * 2019-05-22 2020-11-26 President And Fellows Of Harvard College Human tactile prepulse inhibition assay
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
WO2021072530A1 (en) * 2019-10-15 2021-04-22 Tassili Life Sciences, Corp. Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder.
CA3160793A1 (en) * 2019-12-04 2021-06-10 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
US20210237064A1 (en) 2020-01-31 2021-08-05 Astrin Biosciences, Inc. Biological Fluid Filtration System
AU2021227523B2 (en) * 2020-02-28 2024-05-30 Universitätsspital Basel Controlling effects after 5HT2A agonists administration
KR20220167315A (ko) * 2020-04-13 2022-12-20 유니버지퇴트슈피탈 바젤 Lsd 용량 확인
WO2021207824A1 (en) * 2020-04-17 2021-10-21 Revive Therapeutics Ltd. Use of psilocybin in the treatment of neurological brain injury and migraines
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
US12059533B1 (en) * 2020-05-20 2024-08-13 Pineal Labs Inc. Digital music therapeutic system with automated dosage
WO2021243460A1 (en) * 2020-06-03 2021-12-09 Neonmind Biosciences Inc. Method for weight loss with therapy
WO2021243461A1 (en) * 2020-06-04 2021-12-09 Neonmind Biosciences Inc. Use of lsd, esa, or dmt for weight loss.
WO2021250435A1 (en) 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
WO2022011350A1 (en) * 2020-07-10 2022-01-13 Eleusis Therapeutics Us, Inc. Method of treatment for psilocybin or psilocin infusion
US12122741B2 (en) 2020-08-18 2024-10-22 Cybin Irl Limited Therapeutic phenethylamine compositions and methods of use
GB2615708A (en) 2020-10-21 2023-08-16 Compass Pathfinder Ltd Use of benzodiazepines to increase sensitivity to psilocybin following a chronic SSRI regimen
EP4251139A2 (en) * 2020-11-30 2023-10-04 Wesana Health Inc. Compositions and methods for treating migraine
US20240050454A1 (en) * 2020-11-30 2024-02-15 Jeffrey Jewell Compositions and Methods For Treating Neurological Conditions
WO2022123232A1 (en) * 2020-12-07 2022-06-16 Beckley Psytech Limited Pharmaceutical composition comprising psilocybin or its polymorphs
US20240058469A1 (en) * 2020-12-13 2024-02-22 Silo Pharma, Inc. Use of psilocybin in cancer treatment
BR112023012455A2 (pt) * 2020-12-21 2023-12-05 Psilobrain Therapeutics Inc Composições e métodos para tratamento de transtorno de ansiedade
WO2022150563A1 (en) * 2021-01-08 2022-07-14 New York University Treatment of suicidality with psilocin or psilocybin
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
US20240226124A9 (en) * 2021-02-16 2024-07-11 Augusta University Research Institute, Inc. Cannabidiol for treating neurodegenerative diseases
US20220273628A1 (en) * 2021-02-19 2022-09-01 Universitätsspital Basel Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
US20220265582A1 (en) * 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
WO2022195489A2 (en) * 2021-03-15 2022-09-22 Tryp Therapeutics Inc. Improved methods for the use of psychedelics
CN113017632B (zh) * 2021-03-17 2022-11-11 陈思 一种智慧校园心理咨询辅助方法及系统
CA3113414A1 (en) * 2021-03-29 2022-09-29 Mind Cure Health Inc. Psychedelics protocol computer systems and methods
CA3214120A1 (en) * 2021-03-30 2022-10-06 Wilfred Jefferies Use of psychedelics to treat dementia
EP4312995A1 (en) * 2021-03-30 2024-02-07 COMPASS Pathfinder Limited Psilocybin compositions, methods of making and methods of using the same
CN117355302A (zh) 2021-04-30 2024-01-05 思维医学股份有限公司 Lsd盐晶体形式
WO2022235500A1 (en) * 2021-05-03 2022-11-10 Mind Medicine, Inc. Psychedelics for treatment of pain
WO2022235531A1 (en) * 2021-05-04 2022-11-10 Mind Medicine, Inc. Movement disorders
JP2024522065A (ja) * 2021-05-17 2024-06-11 サイビン アイアールエル リミテッド シロシビンの製剤
IL308816A (en) 2021-05-25 2024-01-01 Atai Therapeutics Inc New n,n-dimethyltryptamine salts and crystalline salt forms
WO2022265878A1 (en) * 2021-06-14 2022-12-22 Mind Medicine, Inc. Controlling effects after 5ht2a agonists administration
CA3225133A1 (en) 2021-07-07 2023-01-12 Matthew Alexander James Duncton N,n-dimethyltryptamine and related psychedlics and uses thereof
WO2023281071A2 (en) * 2021-07-09 2023-01-12 Cybin Irl Limited Integrated data collection devices for use in various therapeutic and wellness applications
WO2023012524A2 (en) * 2021-08-03 2023-02-09 Universitatsspital Basel Lsd and psilocybin dose equivalence determination
JP2024529727A (ja) 2021-08-19 2024-08-08 マインド メディシン， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤
WO2023036473A1 (en) * 2021-09-08 2023-03-16 Cybin Irl Limited Combination drug therapies
WO2023077245A1 (en) * 2021-11-08 2023-05-11 Nova Mentis Life Science Corp. Diagnosing, monitoring and treating neurological disease with psychoactive tryptamine derivatives and mrna measurements
MX2024005632A (es) * 2021-11-09 2024-07-29 Compass Pathfinder Ltd Tratamiento de la depresion resistente al tratamiento con psilocibina.
WO2023086962A1 (en) * 2021-11-12 2023-05-19 Terran Biosciences Inc. Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
EP4429672A4 (en) 2021-11-12 2025-04-30 Terran Biosciences Inc. PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID FORMS THEREOF
JP2024543238A (ja) * 2021-11-23 2024-11-19 コンパス パスファインダー リミテッド インテリジェントトランスクリプションおよびバイオマーカー分析
JP2024546484A (ja) * 2021-12-10 2024-12-24 ジーエーティーシー ヘルス コーポレーション 中毒および神経障害を治療する方法
KR20240122455A (ko) * 2021-12-13 2024-08-12 컴퍼스 패쓰파인더 리미티드 치료-저항성 우울증의 치료에서 사용하기 위한 실로사이빈 및 보조적 세로토닌 재흡수 저해제
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス， インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
EP4457336A4 (en) 2021-12-31 2026-01-14 Empyrean Neuroscience Inc ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
WO2023135595A1 (en) * 2022-01-11 2023-07-20 Psyrx Ltd. Combinations with psilocybin for treating gastrointestinal diseases or disorders
WO2023137325A1 (en) * 2022-01-11 2023-07-20 New York University Treating alcohol use disorder using psilocybin
WO2023164092A1 (en) * 2022-02-25 2023-08-31 Parow Entheobiosciences Llc Treatment of psychiatric disorders, brain injuries, and autism spectrum disorder
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US20250213532A1 (en) * 2022-03-27 2025-07-03 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine for the treatment of bipolar disorder
KR20250005175A (ko) * 2022-03-27 2025-01-09 지에이치 리서치 아일랜드 리미티드 양극성 장애의 치료를 위한 5-meo-dtm
AU2023242469A1 (en) * 2022-03-31 2024-09-05 Cybin Irl Limited Combination of nitrous oxide and 5-ht2a receptor agonists
WO2023215342A1 (en) * 2022-05-03 2023-11-09 Wesana Health Inc. Compositions and methods for treating trigeminal neuralgia
WO2023215338A1 (en) * 2022-05-03 2023-11-09 Wesana Health Inc. Compositions and methods for treating cluster headache
WO2023215344A2 (en) * 2022-05-03 2023-11-09 Wesana Health Inc. Compositions and methods for treating cluster-tic syndrome
US20250352563A1 (en) * 2022-05-03 2025-11-20 Revive Therapeutics Ltd Method and Use of Psilocybin in the Prevention and Treatment of Stroke
IL316639A (en) * 2022-05-05 2024-12-01 Ananda Scient Inc Methods for treating anxiety disorders
EP4522164A1 (en) * 2022-05-13 2025-03-19 Reset Pharmaceuticals, Inc. Administration of a psychedelic compound by intramuscular injection
US20250325571A1 (en) * 2022-06-08 2025-10-23 Tryp Therapeutics Inc. Treatment of binge eating disorder using psychedelics
CA3247344A1 (en) 2022-06-09 2023-12-14 Diamond Therapeutics Inc. AMORPHIC PSILOCYBIN (A-POLYMORPHIC)
US20250360148A1 (en) 2022-06-22 2025-11-27 Cybin Irl Limited Solid dispersions of psilocybin
US20240000795A1 (en) * 2022-06-30 2024-01-04 Terran Biosciences Inc. Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators
US20260000693A1 (en) * 2022-07-19 2026-01-01 Lobe Sciences Ltd. Serotonergic psychedelic agent for treating selective mutism
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
GB202214721D0 (en) * 2022-10-06 2022-11-23 Rewire Therapeutics Ltd A treatment for mental disorders
WO2024079648A1 (en) * 2022-10-11 2024-04-18 Sintalica S.R.L. Delivery system for the controlled release of psychedelic compound, pharmaceutical composition and uses thereof
CN120897742A (zh) * 2022-11-15 2025-11-04 福睿德姆生物科学公司 通过抑制9型磷酸二酯酶增强血清素能致幻药物在治疗或预防某些神经精神障碍中的功效
WO2024130044A1 (en) * 2022-12-14 2024-06-20 Luminous Mind Inc. Treatment of psychological factors affecting other medical conditions (pfaomc)
EP4673125A1 (en) * 2023-02-28 2026-01-07 Mind Medicine, Inc. R-mdma for treatment of pain
EP4704826A1 (en) * 2023-04-28 2026-03-11 Yale University Compositions and methods for treating post-traumatic stress disorder
WO2024234014A1 (en) * 2023-05-11 2024-11-14 Spiritus Bioscience, Inc. Sublingual spray formulations of psychedelics
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
JP7608525B1 (ja) 2023-06-27 2025-01-06 株式会社キャタラー ガソリンエンジン用排ガス浄化触媒装置
US12157722B1 (en) 2023-08-03 2024-12-03 Gilgamesh Pharmaceuticals, Inc. Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
WO2025038542A1 (en) * 2023-08-11 2025-02-20 The Regents Of The University Of California Psilocybin for treating phantom pain
CN117695377B (zh) * 2023-12-14 2025-01-07 贵州医科大学 Vsig2在制备治疗自身免疫性疾病产品中的应用

Family Cites Families (507)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA672478A (en) 1963-10-15 Heim Roger Psilocybin and psilocin
LU36879A1 (https=) 1958-02-21
GB911946A (en) 1958-02-21 1962-12-05 Sandoz Ltd Psilocybin and psilocin and processes for their preparation
US3075992A (en) 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles
NL243249A (https=) 1958-09-12
US3192111A (en) * 1959-02-16 1965-06-29 Sandoz Ltd Method of inducing therapeutic tranquilization with psilocybin and psilocin
IE24138L (en) 1959-02-18 1959-08-21 Sandoz Ag Psilocybin and psilocin
JPS5576859A (en) 1978-12-01 1980-06-10 Fujimoto Seiyaku Kk Novel preparation of 4-hydroxyindole
JPS5728046A (en) 1980-07-28 1982-02-15 Nissan Chem Ind Ltd Preparation of 4-substituted indole
US4499096A (en) 1983-11-18 1985-02-12 Lotsof Howard S Rapid method for interrupting the narcotic addiction syndrome
EP0152379A3 (de) 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
IL76591A0 (en) 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US4587243A (en) 1985-07-15 1986-05-06 Lotsof Howard S Rapid method for interrupting the cocaine and amphetamine abuse syndrome
IL80230A (en) 1985-10-04 1993-03-15 South African Inventions Protein binding reagent
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
EP0493380B1 (en) 1989-09-05 1997-10-29 University Of Utah Research Institute Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US5935925A (en) 1990-05-08 1999-08-10 Synaptic Pharmaceutical Corporation Methods of treating migraine and compounds useful for such methods
US5626863A (en) 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
ES2193132T3 (es) 1990-10-19 2003-11-01 Univ New York Procedimiento para transplantar celulas en el cerebro y utilizaciones terapeuticas del mismo.
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
FR2675504B1 (fr) 1991-04-16 1995-01-27 Delalande Sa Derives d'aryl-3 oxazolidinone, leur procede de preparation et leur application en therapeutique.
US5468486A (en) 1992-01-21 1995-11-21 The University Of Tennessee Research Corporation Vaccine containing a protein alkaloid conjugate for the treatment of fescue toxicosis
US5482706A (en) 1992-04-17 1996-01-09 Takeda Chemical Industries, Ltd. Transmucosal therapeutic composition
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
DK0628042T3 (da) 1992-12-24 2001-11-12 Pharmacia & Upjohn Spa Serotoninerge ergolinderivater
ES2068762B1 (es) 1993-07-21 1995-12-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
US5545617A (en) 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US20060019963A1 (en) 1994-06-17 2006-01-26 Smithkline Beecham Corporation Compounds
MX9701430A (es) 1994-07-25 1997-12-31 Nda Int Inc Un metodo de tratamiento de dependencia quimica en mamiferos y una composicion para el mismo.
US5874477A (en) 1994-08-12 1999-02-23 The University Of Hawaii Method of treatment for malaria utilizing serotonin receptor ligands
US5696125A (en) 1995-02-24 1997-12-09 Research Foundation Of The State University Of New York Substance abuse-induced hemorrhagic stoke in an animal model
US5643586A (en) 1995-04-27 1997-07-01 Perricone; Nicholas V. Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
NZ311474A (en) 1995-06-09 1997-09-22 Euro Celtique Sa Formulations for providing prolonged local anesthesia
US5879690A (en) 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
DE19542281C2 (de) 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
FR2744361B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744363B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de thiazolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744362B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744364B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application d'ureidoacetamides a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
WO1997035584A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
TW448171B (en) 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
US5958919A (en) 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US5804592A (en) 1997-05-30 1998-09-08 Unimed Pharmaceuticals, Inc. Method for improving disturbed behavior and elevating mood in humans
EP1019041A4 (en) 1997-05-07 2002-04-17 Unimed Pharmaceutical Inc METHODS TO IMPROVE BEHAVIORAL BEHAVIOR AND RAISE MIND IN PEOPLE
US6558956B1 (en) 1997-06-24 2003-05-06 The University Of Wyoming Method and apparatus for detection of a controlled substance
GB9715082D0 (en) 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US20010004644A1 (en) 1997-07-21 2001-06-21 Levin Bruce H. Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
WO1999009828A1 (en) 1997-08-25 1999-03-04 Pentech Pharmaceuticals, Inc. Method for amelioration of social phobia
EP1009407B1 (en) 1997-09-04 2004-04-28 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
DE19738855C2 (de) 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6037346A (en) 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
ITTO980264A1 (it) 1998-03-26 1999-09-26 Silvio Rossi Applicazione di un estratto basico non quaternario della peschiera fuchsiaefolia ad attivita' antimalarica
AU4254799A (en) 1998-06-22 2000-01-10 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
WO2000003679A2 (en) 1998-07-14 2000-01-27 Adams Food Ltd. Nutritionally active composition for hardening fingernails
WO2000003746A2 (en) 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
JP2002520353A (ja) 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー ストレスの処置のための組成物
AU5243999A (en) 1998-07-31 2000-02-21 Vela Pharmaceuticals Inc. Methods and compositions for treating and preventing substance abuse using moclobemide
CN1269484C (zh) 1998-09-18 2006-08-16 艾尔科实验室公司 用于治疗青光眼的5－羟色胺激活性激动剂
US20060025387A1 (en) 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
US6962717B1 (en) 1999-01-29 2005-11-08 Disphar International B.V. Pharmaceutical compositions
CN100548290C (zh) 1999-02-24 2009-10-14 辛辛那提大学 氨基磺酸酯衍生物用于治疗冲动控制障碍的用途
AU3760300A (en) 1999-03-19 2000-10-09 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EP1165054A4 (en) 1999-04-06 2005-02-09 Pharmaquest Ltd PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT DELIVERY OF METHYLPHENIDATE
AP2001002290A0 (en) 1999-04-07 2001-12-31 Pfizer Prod Inc Use of CYP2D6 inhibitors in combination therapies.
US6495498B2 (en) 1999-05-27 2002-12-17 Johnson & Johnson Consumer Companies, Inc. Detergent compositions with enhanced depositing, conditioning and softness capabilities
US6126924A (en) 1999-05-27 2000-10-03 Scales-Medeiros; Virginia A. Light responsive self-tanning products and methods for use
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
MXPA02001882A (es) 1999-08-23 2002-08-20 Univ Tulane Modulacion del transportador de leptina a traves de la barrera hemato-encefalica.
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
WO2001026642A2 (en) 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
ES2162746B1 (es) 1999-10-21 2003-02-16 Lipotec Sa Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
CA2400803A1 (en) 2000-01-18 2001-07-26 Richard A. Stone Ocular growth and nicotinic antagonists
US20030096831A1 (en) 2000-01-18 2003-05-22 Stone Richard A. Ocular growth and nicotinic antagonists
FR2804603B1 (fr) 2000-02-04 2004-01-23 Rhodia Chimie Sa Procede continu pour formuler sous forme de granules une ou plusieurs matieres actives pharmaceutiques
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
AU2001243369A1 (en) 2000-03-14 2001-09-24 Massachusetts Institute Of Technology Composition and method to treat weight gain and obesity attributable to psychotropic drugs
CA2404461A1 (en) 2000-03-27 2001-10-04 Pe Corporation (Ny) Human g-protein coupled receptors
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
US6380176B2 (en) 2000-03-28 2002-04-30 Ajinomoto Co., Inc. Method for inhibiting non-intentional behavior with a running neuron inhibitory substance
DE10018834A1 (de) 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
AU6106801A (en) 2000-04-28 2001-11-12 Gary W. Neal Trans-clitoral administration of therapy
JP4763957B2 (ja) 2000-05-10 2011-08-31 オバン・エナジー・リミテッド メディアミリング
US20070059367A1 (en) 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US20020019421A1 (en) 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
CA2416650C (en) 2000-07-19 2010-09-21 Pitmy International N.V. Enhancement of the action of central and peripheral nervous system agents
AU2001291114A1 (en) 2000-09-19 2002-04-02 Microbia, Inc. Modulation of secondary metabolite production by zinc binuclear cluster proteins
US9474776B2 (en) 2000-10-04 2016-10-25 Paul Edward Stamets Integrative fungal solutions for protecting bees
US9399050B2 (en) 2000-10-04 2016-07-26 Paul Edward Stamets Controlling insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi
US20070100000A1 (en) 2000-11-01 2007-05-03 Epstein Mel H Methods of providing neuroprotection
US20030119884A1 (en) 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
BR0115783A (pt) 2000-11-30 2003-09-16 Pfizer Prod Inc Combinação de agonistas de gaba e inibidores de sorbitol desidrogenase
EP1337272A2 (en) 2000-11-30 2003-08-27 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
US20020137785A1 (en) 2001-03-26 2002-09-26 George Kindness Inflammatory mechanism modulator composition and methods with anti-asthmatic properties
US20050096396A1 (en) 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
WO2002078643A2 (en) 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
US6632217B2 (en) 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
AU2002303577B2 (en) 2001-05-04 2006-06-08 Merck & Co., Inc. Method and compositions for treating migraines
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20040023952A1 (en) 2001-06-20 2004-02-05 Leventhal Audie G. Enhanced brain function by gaba-ergic stimulation
WO2003016903A2 (de) 2001-08-20 2003-02-27 Walter Pils Vorrichtung und verfahren zum nachweis eines analyten
US6541043B2 (en) 2001-08-28 2003-04-01 Dexgen Pharmaceuticals, Inc. Method and synergistic composition for treating attention deficit/hyperactivity disorder
US20030099711A1 (en) 2001-08-29 2003-05-29 David Meadows Sustained release preparations
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
WO2003026564A2 (en) 2001-09-27 2003-04-03 Pharmacia Ab Pharmaceutical compositions for the treatment of urinary disorders
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
US20060264508A1 (en) 2001-10-16 2006-11-23 Stone Richard A Modulation of ocular growth and myopia by gaba drugs
US20030082225A1 (en) 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
WO2003041645A2 (en) 2001-11-09 2003-05-22 Chiron Corporation Method of vaccinating a human patient to prevent metastatic tumors
GB0127832D0 (en) 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
AU2002352868A1 (en) 2001-11-27 2003-06-10 Merck & Co., Inc. 4-aminoquinoline compounds
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
AU2002219964A1 (en) 2001-11-29 2003-06-17 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US7241797B2 (en) 2002-01-23 2007-07-10 University Of Cincinnati Method of increasing milk production
US20030171435A1 (en) 2002-01-23 2003-09-11 Drug Abuse Sciences, Inc. New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
EP1480624B1 (en) 2002-02-07 2006-11-29 Pharmacia Corporation Pharmaceutical tablet
PL372290A1 (en) 2002-02-07 2005-07-11 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
US20030153552A1 (en) 2002-02-14 2003-08-14 Mash Deborah C. Method of treating chemical dependency in mammals and a composition therefor
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
DE10208335A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
US20030199439A1 (en) 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
US20030232805A1 (en) 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
US20060034872A1 (en) 2002-04-29 2006-02-16 Woolf Clifford J Compositions and methods for preventing abuse of orally administered medications
AUPS317102A0 (en) 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Transdermal aerosol compositions
WO2004003145A2 (en) 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
US20040006043A1 (en) 2002-07-02 2004-01-08 Ramot University Authority For Applied Research & Industrial Development Ltd. Methods, pharmaceutical compositions and pharmaceutical kits for enhancing the therapeutic efficiency of cancer chemotherapeutic agents
US10738268B2 (en) 2016-08-21 2020-08-11 Insectergy, Llc Cannabis nanoemulsion methods
US20050148673A1 (en) 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
EP2351770A1 (en) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
US7838034B2 (en) 2002-07-30 2010-11-23 Grunenthal Gmbh Intravenous pharmaceutical form of administration
JPWO2004014429A1 (ja) 2002-08-09 2005-12-02 三菱ウェルファーマ株式会社 精神疾患発症脆弱性制御剤
US20030114512A1 (en) 2002-09-09 2003-06-19 Collier Robert J Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
AU2003278832A1 (en) 2002-09-13 2004-04-30 Carnegie Mellon University Optical biosensors and methods of use thereof
WO2004026290A1 (en) 2002-09-19 2004-04-01 Merck & Co., Inc. Method for treating depression and/or anxiety
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
DE10244504A1 (de) 2002-09-25 2004-04-08 Capsulution Nanoscience Ag Schnellfreisetzende Darreichungsform mit schwerlöslichem Wirkstoff
AU2003273977B2 (en) 2002-10-11 2007-07-12 Idea Ag Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
AU2003304211A1 (en) 2002-10-30 2005-01-04 The Regents Of The University Of California Direct micro-patterning of lipid bilayers using uv light and selected uses thereof
DE10250944B9 (de) 2002-10-31 2004-09-16 Cell Center Cologne Gmbh Verwendung eines Stifts zur Applikation von Pflege- oder Wirkstoffen in die Nase
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
EP1585520A1 (en) 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
DK2009000T3 (da) 2003-01-16 2011-09-05 Acadia Pharm Inc Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme
CN1741803A (zh) 2003-01-23 2006-03-01 阿卡蒂亚药品公司 N－脱甲基氯氮平在治疗人神经精神疾病中的用途
US20040186155A1 (en) 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
WO2004071431A2 (en) 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CA2519117C (en) 2003-03-17 2010-03-02 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
EP1605972A2 (en) 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
MXPA05012850A (es) 2003-05-29 2006-05-17 New River Pharmaceuticals Inc Compuestos de anfetamina resistentes al abuso.
JP2006526652A (ja) 2003-06-03 2006-11-24 ベス・イスラエル・ディーコニス・メディカル・センター 血管狭窄を治療するための方法及び化合物
US20070065463A1 (en) 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
JP4174016B2 (ja) 2003-07-11 2008-10-29 株式会社ビーエル 競合法によるサイロシン類のイムノクロマトグラフィー検出法及びテストキット
US7276608B2 (en) 2003-07-11 2007-10-02 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US20050203011A1 (en) 2003-09-19 2005-09-15 The Regents Of The University Of California Mitigating symptoms and behaviors of substance abuse by modulating GDNF or BDNF pathway activity
US20050070501A1 (en) 2003-09-29 2005-03-31 New York Blood Center, Inc. Water dispersible film
JP4641942B2 (ja) 2003-10-03 2011-03-02 フェーイレン・ナムローゼ・フェンノートシャップ ヒトおよび動物におけるｉｇｆ−１血清レベルの低下と関連した種々の疾患状態の治療用の治療用組成物の製造のための血清中ｉｇｆ−１レベルを増加できる化合物の使用
WO2005037199A2 (en) 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
US20070053954A1 (en) 2003-10-24 2007-03-08 Rowe Stephen C Macromer-melt formulations
WO2005039502A2 (en) 2003-10-24 2005-05-06 Azopax Therapeutics Llc Macromer-melt formulations
JP2005132747A (ja) 2003-10-29 2005-05-26 Ajinomoto Co Inc 老齢伴侶動物の老化行動改善剤
EP1701725B1 (en) 2003-12-16 2013-07-31 Relevare Aust. Pty Ltd Compositions comprising flupirtine and an opioid for use in the treatment of neuropathic pain
US20050260258A1 (en) 2003-12-18 2005-11-24 The Texas A&M University System Use of vitelline protein B as a microencapsulating additive
WO2005063248A1 (en) 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
WO2005063296A2 (en) 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
GB0400802D0 (en) 2004-01-14 2004-02-18 Daniolabs Ltd Compounds for the treatment of disease
WO2005072705A1 (en) 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
EP1734920A2 (en) 2004-02-13 2006-12-27 Neuromolecular Inc. Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
CA2556214A1 (en) 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
US7981441B2 (en) 2004-02-18 2011-07-19 The Board Of Trustees Of The Leland Stanford Junior University Drug delivery systems using mesoporous oxide films
US20050222270A1 (en) 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
FR2867075B1 (fr) 2004-03-03 2006-07-14 Ethypharm Sa Procede de preparation de microspheres biodegradables calibrees
EP1729759A4 (en) 2004-03-12 2008-04-02 Mclean Hospital Corp SALVINORINE DERIVATIVES AND ITS USES
US20060270592A1 (en) 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2005102366A2 (en) 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
RU2253461C1 (ru) 2004-04-30 2005-06-10 Общество с ограниченной ответственностью "Паркинфарм" Фармацевтическая комбинация, оказывающая влияние на функционирование цнс, способ коррекции состояний, связанных с нарушениями функционирования цнс; фармацевтический набор; средство, способствующее проникновению через гематоэнцефалический барьер лекарственных субстанций и метаболитов; фармацевтическое средство для эндоназального применения
US20050255091A1 (en) 2004-05-14 2005-11-17 Loomis Gary L Hydrogels for biomedical applications
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US20050265955A1 (en) 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
NL1026634C2 (nl) 2004-07-12 2006-01-16 Willem Jacob Van Der Burg Psychofarmaceutisch preparaat en werkzame stof daarin.
US7799802B2 (en) 2004-08-03 2010-09-21 Institstute of Oriental Medical Science Inc. Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation
US20060030625A1 (en) 2004-08-06 2006-02-09 Cheryle Ram Hart Dietary neurotransmitter precursors for balanced synthesis of neurotransmitters
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
SG155257A1 (en) 2004-09-24 2009-09-30 Beth Israel Hospital Methods of diagnosing and treating complications of pregnancy
AU2005300045A1 (en) 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
US20060240043A1 (en) 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
WO2006053383A1 (en) 2004-11-22 2006-05-26 Anadis Ltd Bioactive compositions
FR2878161B1 (fr) 2004-11-23 2008-10-31 Flamel Technologies Sa Forme medicamenteuse orale, solide et concue pour eviter le mesusage
FR2878158B1 (fr) 2004-11-24 2009-01-16 Flamel Technologies Sa Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
US20060110327A1 (en) 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US7294649B2 (en) 2004-12-17 2007-11-13 Roche Diagnostics Operatins, Inc. Methamphetamine derivatives and conjugates for immunoassay
KR20070087678A (ko) 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
PL1844189T3 (pl) 2005-01-10 2021-10-25 Smiths Detection Inc. Sposób przygotowania wymazówki
DE102005004343A1 (de) 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
FR2881652B1 (fr) 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
MX2007011250A (es) 2005-03-21 2007-11-14 Ivax Pharmaceuticals Sro Inhibidor de la cristalizacion y su uso en capsulas de gelatina.
PL1861427T3 (pl) 2005-03-23 2013-01-31 Bpsi Holdings Llc Kompozycje aglomerowanej skrobi
JP2008534562A (ja) 2005-03-28 2008-08-28 オレクソ・アクチエボラゲット 偏頭痛の治療に有用な新しい製薬組成物
US20060229293A1 (en) 2005-04-06 2006-10-12 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
EP1865980A4 (en) 2005-04-08 2009-11-11 Shire Llc ABUSEFUL AMPHETAMINE PRODRUGS
JP2008537961A (ja) 2005-04-15 2008-10-02 ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ Ｇｐｃｒモジュレーター
EP1868664A2 (en) 2005-04-15 2007-12-26 Interface Biologics Inc. Methods and compositions for the delivery of biologically active agents
AU2006239930A1 (en) 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof
JP4899012B2 (ja) 2005-05-06 2012-03-21 スミス・ディテクション・インコーポレイテッド パーオキシドベースの爆発物の改良された化学的検出
US8859585B2 (en) 2005-05-25 2014-10-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Scopolamine for the treatment of depression and anxiety
GB0511060D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
JP5284779B2 (ja) 2005-06-07 2013-09-11 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
EP2371394A1 (en) 2005-06-16 2011-10-05 Mohammed Saeed Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent
US7645802B2 (en) 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070092586A1 (en) 2005-10-26 2007-04-26 Alamo Pharmaceuticals Compositions and methods for the administration psychotropic drugs which modulate body weight
DE102005055866A1 (de) 2005-11-23 2007-05-24 Hte Ag The High Throughput Experimentation Company Verfahren zur Herstellung von Aryl-Aryl gekoppelter Verbindungen
EP1991207A2 (en) 2006-01-21 2008-11-19 Abbott GmbH & Co. KG Dosage form and method for the delivery of drugs of abuse
JP2009525124A (ja) 2006-02-02 2009-07-09 メドロジックス・ディバイス・コーポレーション ゾル−ゲル組成物を含む生物活性材料送達系
US20070203216A1 (en) 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
US20070190130A1 (en) 2006-02-16 2007-08-16 Mark William A Protein hydrolysate excipients
US20080075789A1 (en) 2006-02-28 2008-03-27 The Regents Of The University Of California Genes differentially expressed in bipolar disorder and/or schizophrenia
WO2007103687A2 (en) 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
FR2898271B1 (fr) 2006-03-09 2009-01-16 Pierre Fabre Medicament Sa Nouvelle utilisation d'agents antihistaminiques pour le traitement preventif ou procede de syndromes inflammatoires, en particulier ceux declenches par les toga virus.
WO2007111880A2 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
WO2006079999A2 (en) 2006-04-09 2006-08-03 Barth Frederik H Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
EP2010584A4 (en) 2006-04-14 2010-07-21 Interface Biologics Inc DIPPLETED POLYMERS AND APPLICATIONS THEREOF
GB0608647D0 (en) 2006-05-02 2006-06-14 Haritou Susan J A Methods of diagnosis and treatment
JP5052602B2 (ja) 2006-05-12 2012-10-17 シャイア エルエルシー 制御用量薬物送達システム
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
ES2383768T3 (es) 2006-06-28 2012-06-26 Chelsea Therapeutics Inc. Composiciones farmacéuticas que comprenden droxidopa
CA2656112A1 (en) 2006-06-30 2008-05-08 Hanje Chen Bioresponsive polymers
EP2051735B1 (en) 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
CA2692440A1 (en) 2006-07-20 2008-01-24 Cascade Therapeutics Inc. Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands
US20080026189A1 (en) 2006-07-27 2008-01-31 Chun-Wei Lin Thin key structure for generating dazzling light
MX2009001966A (es) 2006-08-23 2009-06-19 Univ Montana Metodo de reduccion del daño celular neuronal.
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2008026046A1 (en) 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
EP2081429A4 (en) 2006-08-31 2010-01-06 Biogen Idec Inc PROCESS FOR PERIPHERAL ADMINISTRATION OF NOGO RECEPTOR POLYPEPTIDES
AU2007299920A1 (en) 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
CA2664935A1 (en) 2006-09-26 2008-04-03 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
WO2008038291A1 (en) 2006-09-27 2008-04-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy
DE602007010818D1 (de) 2006-10-27 2011-01-05 Janssen Pharmaceutica Nv Verfahren zur behandlung disruptiver verhaltensstörungen
AU2007309390A1 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Methods and combination therapies for treating Alzheimer's disease
BRPI0718323A2 (pt) 2006-10-31 2013-11-26 Janssen Pharmaceutica Nv Tratamento de transtornos invasivos do desenvolvimento.
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8653106B2 (en) 2010-07-30 2014-02-18 Pisgah Laboratories, Inc. Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder
US20080293695A1 (en) 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US9823737B2 (en) * 2008-04-07 2017-11-21 Mohammad A Mazed Augmented reality personal assistant apparatus
US10529003B2 (en) * 2008-04-07 2020-01-07 Mohammad A. Mazed Optical biomodule for detection of diseases at an early onset
ES2364865T3 (es) 2006-12-11 2011-09-15 Kempharm, Inc. Conjugados de ornitina de la anfetamina y procedimientos de fabricación y de utilización de los mismos.
ES2302650B1 (es) 2007-01-11 2009-02-16 Tedec-Meiji Farma, S.A. Composicion de rapida desintegracion en la cavidad bucal.
CA2677205A1 (en) 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
EP2433655A3 (en) 2007-02-08 2013-05-15 Kempharm, Inc. Homoarginine-prodrugs of amphetamine
CN101657193A (zh) 2007-03-09 2010-02-24 切尔西治疗公司 用于治疗纤维肌痛的屈昔多巴及其药物组合物
WO2008112773A2 (en) 2007-03-12 2008-09-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
US20080226715A1 (en) 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
DE102007014286A1 (de) 2007-03-19 2008-09-25 Universität Tübingen Fluorsubstituierte Amphetamine und Amphetaminderivate und deren Verwendung
CN104906669A (zh) 2007-03-30 2015-09-16 菲利普莫里斯生产公司 用于输送药剂的装置和方法
AT505086B1 (de) 2007-04-02 2009-06-15 Planta Naturstoffe Vertriebsge Pharmazeutisches mittel gegen juckreiz und juckreizbedingten schmerz
WO2008122990A1 (en) 2007-04-04 2008-10-16 Almet Corporation Limited Compacting upflow extractor and method of using it
US8747832B2 (en) 2007-04-12 2014-06-10 Rutgers, The State University Of New Jersey Biodegradable polyanhydrides with natural bioactive molecules
US7687660B2 (en) 2007-04-18 2010-03-30 Teva Pharmaceutical Industries Ltd. Process for preparing intermediates of HMG-CoA reductase inhibitors
CN101765582A (zh) 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 氘标记的氯胺酮
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
EP2182957A4 (en) 2007-07-31 2012-07-18 Limerick Biopharma Inc PHOSPHORYLATED PYRONANALOGES AND CORRESPONDING METHODS
CN101815519B (zh) 2007-08-03 2013-08-21 吉瑞工厂 包含多巴胺受体配体的药物组合物和使用多巴胺受体配体的治疗方法
AU2016208412A1 (en) 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
MX2010001390A (es) 2007-08-06 2010-08-02 Synosia Therapeutics Inc Métodos para el tratamiento de dependencia.
FR2919861A1 (fr) 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate d'isopranol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
US8222254B2 (en) 2007-08-07 2012-07-17 Prosarix Limited 1, 2, 4-triazole derivatives as serotonergic modulators
US8067028B2 (en) 2007-08-13 2011-11-29 Confluent Surgical Inc. Drug delivery device
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
CA2701186C (en) 2007-10-05 2017-09-19 Evonik Canada Inc. Oligofluorinated cross-linked polymers and uses thereof
US20110053859A1 (en) 2007-10-10 2011-03-03 The U. S. Government Respresented by the Department of Veterans Affairs Methods to reduce the effects of sleep deprivation
WO2009055001A2 (en) 2007-10-23 2009-04-30 Fred Hutchinson Cancer Research Center Methods of treating aging and methods of screening candidate agents therefor
WO2009061436A1 (en) 2007-11-06 2009-05-14 University Of Florida Research Foundation Compound for activating 5-ht2c receptors in combination with an amphetamine compound
DE102007063210A1 (de) 2007-12-20 2009-06-25 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung von Phantomphänomenen
WO2009079765A1 (en) 2007-12-21 2009-07-02 Cascade Therapeutics Inc. Compounds with activity at the 5-ht2c receptor
WO2009089234A2 (en) 2008-01-07 2009-07-16 Auspex Pharmaceuticals Substituted dibenzhydrylpiperazines
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
US8137690B2 (en) 2008-01-17 2012-03-20 Health Innovations, Llc Taste titration therapies
AU2016203452B2 (en) * 2008-01-22 2018-02-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2014203195B2 (en) * 2008-01-22 2016-03-31 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2009097596A1 (en) 2008-01-31 2009-08-06 Paul Griffin Compositions and methods for the treatment of chronic infections
US8329663B2 (en) 2008-01-31 2012-12-11 Paul Griffin Compositions and methods for the treatment of chronic infections
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
RU2540871C2 (ru) 2008-02-01 2015-02-10 Альфа-О Пептидес Аг Самоорганизующиеся пептидные наночастицы, полезные в качестве вакцин
US20090198145A1 (en) 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
EP2254865A1 (en) 2008-02-11 2010-12-01 Organix, Inc. Indole compounds and methods of use thereof
US8859579B2 (en) 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
EA201001521A1 (ru) 2008-03-26 2011-04-29 Лонца Лтд. Способ синтеза этинилциклопропана
US20170276676A1 (en) 2008-03-27 2017-09-28 Gus J. Slotman System for assessing drug efficacy and response of a patient to therapy
WO2009118763A1 (en) 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
US20090252786A1 (en) 2008-03-31 2009-10-08 Christoph Hanz Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor
EP2106799A1 (en) 2008-03-31 2009-10-07 OWEN Holding LTD Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a GABA receptor
FR2930147B1 (fr) 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
AU2009241847B2 (en) 2008-04-28 2014-07-10 Zogenix, Inc. Novel formulations for treatment of migraine
US20110086063A1 (en) 2008-06-04 2011-04-14 Cornell University Vaccines for prevention and treatment of addiction
US10388179B2 (en) 2008-06-18 2019-08-20 Accenture Global Solutions Limited Analytics platform
EP2285362B1 (en) 2008-06-19 2017-08-09 LTS LOHMANN Therapie-Systeme AG Composition for transdermal delivery of cationic active agents
WO2010001391A1 (en) 2008-06-30 2010-01-07 Oron Zachar Dermal application of vasoconstrictors
US9642819B2 (en) 2008-07-10 2017-05-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
US8617607B2 (en) 2008-07-10 2013-12-31 Tyrx, Inc. Sustained release formulations of psychoactive drugs
EP2331088A4 (en) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
FR2936710B1 (fr) 2008-10-07 2011-01-07 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
CN102292094B (zh) 2009-01-20 2013-08-14 洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心 增强神经药方疗效的山梨酸与苯甲酸及其衍生物
UA105657C2 (uk) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
WO2010124089A2 (en) 2009-04-22 2010-10-28 Synosia Therapeutics, Inc. Methods for treating dependence
US20120159656A1 (en) 2009-04-24 2012-06-21 Galenea Corp. Compositions and methods for evaluating cognitive defects
WO2010136803A1 (en) 2009-05-26 2010-12-02 Shire Llc Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
GB201111485D0 (en) 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
US20110306596A1 (en) 2009-07-27 2011-12-15 Auspex Pharmaceuticals, Inc. Benzazepine inhibitors of gamma-secretase
WO2011097269A1 (en) 2010-02-06 2011-08-11 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20120302590A1 (en) 2009-08-13 2012-11-29 The General Hospital Corporation Methods and compositions to prevent addiction
US20110038915A1 (en) 2009-08-14 2011-02-17 Eduardo Jose Gonzalez Chewing Gum Formula for Enhancing Psycho-Spirituality
WO2011028875A1 (en) 2009-09-03 2011-03-10 Wake Forest University Health Sciences Immunogenic conjugates for producing immune responses to drugs of abuse and methods of use
WO2011027060A2 (fr) 2009-09-04 2011-03-10 Centre National De La Recherche Scientifique - Crns - Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique
FR2951378B1 (fr) 2009-10-16 2012-06-01 Flamel Tech Sa Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
CA2774036C (en) 2009-10-16 2018-04-03 Dsm Ip Assets B.V. Coatings comprising bis-(alpha-amino-diol-diester) containing polyesteramide
US20120321706A1 (en) 2009-10-19 2012-12-20 Intec Pharma Ltd. Novel gastroretentive dosage forms of poorly soluble drugs
WO2011072398A1 (en) 2009-12-18 2011-06-23 Interface Biologics, Inc. Local delivery of drugs from self assembled coatings
CA2829180C (en) 2010-03-05 2019-01-15 Newagriculture, Inc. Leaf protein-lipid-soluble material complexes
US20110217289A1 (en) 2010-03-05 2011-09-08 Basf Se Melt-Coated Dosage Forms
ES2887335T3 (es) 2010-03-17 2021-12-22 Univ Cornell Vacuna contra las drogas de abuso basada en adenovirus alterado
WO2011138142A1 (en) 2010-05-07 2011-11-10 Ecole Polytechnique Federale De Lausanne (Epfl) Compositions and use of sulfasalazine
CA2797158A1 (en) 2010-05-10 2011-11-17 Segetis, Inc. Alkyl ketal esters as dispersants and slip agents for particulate solids, methods of manufacture, and uses thereof
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
JP2012020991A (ja) 2010-06-16 2012-02-02 Takasago Internatl Corp 経皮吸収促進剤、及びこれを含有する皮膚外用製剤
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
EP2595632A1 (en) 2010-07-23 2013-05-29 DemeRx, Inc. Noribogaine compositions
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
WO2012022928A2 (en) 2010-08-20 2012-02-23 Heptares Therapeutic Ltd Biological materials and uses thereof
CN103221070B (zh) 2010-08-30 2019-07-12 哈佛大学校长及研究员协会 用于狭窄病变和溶解血栓疗法的切变控制释放
US20130310422A1 (en) 2010-09-01 2013-11-21 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US20120129834A1 (en) 2010-09-17 2012-05-24 Buck Institute For Research On Aging Serotonin receptor antagonists for use in the treatment of huntington's disease
DK2618826T3 (en) 2010-09-20 2016-08-01 A Carlsson Res Ab Phenylpiperdine FOR TREATMENT OF DEMENTIA
AU2011313814B2 (en) 2010-10-07 2015-12-24 Eaglepharma Pty Ltd Combination therapy for the treatment of depression and other non-infectious diseases
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
US20130230587A1 (en) 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
EP2640370B1 (en) 2010-11-15 2018-03-14 Neuroderm Ltd Compositions for transdermal delivery of active agents
EP2649443A2 (en) 2010-12-06 2013-10-16 Ramot at Tel-Aviv University Ltd Methods and kits for detection of drugs
IL298116A (en) 2010-12-22 2023-01-01 Syqe Medical Ltd Method and system for drug delivery
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
FR2971423B1 (fr) 2011-02-15 2014-01-10 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
US8742096B2 (en) 2011-03-28 2014-06-03 Demerx, Inc. Methods and compositions for preparing noribogaine from voacangine
CN103502817B (zh) 2011-03-28 2016-01-20 前视红外系统股份有限公司 包括药物的分析物的检测方法
JOP20120083B1 (ar) 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
US20120282255A1 (en) 2011-04-07 2012-11-08 Greg Plucinski Methods and compositions for the treatment of alcoholism and alcohol dependence
KR20120128440A (ko) 2011-05-17 2012-11-27 삼성전자주식회사 표적 물질 검출용 키트 및 이를 이용한 표적 물질 검출 방법
US20140163070A1 (en) 2012-05-17 2014-06-12 Bruce Roseman Treatment for cerebral palsy impaired speech in children
WO2012158892A2 (en) 2011-05-19 2012-11-22 Bruce Roseman A method of treating apraxia of speech in children
MX2013015373A (es) 2011-06-23 2014-02-11 Map Pharmaceuticals Inc Nuevos analogos de fluoroergolina.
WO2013040471A2 (en) 2011-09-15 2013-03-21 Demerx, Inc. Noribogaine salt ansolvates
US20130116215A1 (en) 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
FR2983409B1 (fr) 2011-12-06 2013-12-27 Ethypharm Sa Comprime susceptible de lutter contre le detournement par voie injectable
CA3122767C (en) 2011-12-08 2023-03-28 Demerx, Inc. Stereoselective total synthesis of noribogaine
CA2855994A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
JP2015509075A (ja) 2011-12-09 2015-03-26 デメレックス， インコーポレイテッド ノルイボガインの硫酸エステル
EP2607352A1 (en) 2011-12-22 2013-06-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-diketoamides for treatment of psychiatric disorders
EP2610245A1 (en) 2011-12-28 2013-07-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-sulfonamides for treatment of psychiatric disorders
US8877921B2 (en) 2012-01-25 2014-11-04 Demerx, Inc. Synthetic voacangine
EP2807167A4 (en) 2012-01-25 2016-01-20 Demerx Inc INDOIND AND BENZO FURANKED ISOCHINUCLIDEN DERIVATIVES AND METHOD FOR THE MANUFACTURE THEREOF
WO2013112163A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US20130295170A1 (en) 2012-05-03 2013-11-07 Kydes Pharmaceuticals Llc Compositions for control of drug abuse
US20130295016A1 (en) 2012-05-07 2013-11-07 David J. Gerber Signatures of electroencephalographic oscillations
CN108498532B (zh) 2012-05-09 2021-07-23 坎泰克斯制药股份有限公司 骨髓抑制的治疗
US8784835B2 (en) 2012-07-02 2014-07-22 Trent Austin Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
WO2014008118A2 (en) 2012-07-02 2014-01-09 The General Hospital Corporation Method for concurrent treatment of pain and depression
EP2690102A1 (en) 2012-07-24 2014-01-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bicyclic aza-amides for treatment of psychiatric disorders
WO2014028796A2 (en) 2012-08-17 2014-02-20 Smartek International Llc Preparation of desiccated liposomes for use in compressible delivery systems
AU2013305563B2 (en) 2012-08-24 2018-09-27 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
US20140066881A1 (en) 2012-08-31 2014-03-06 Zoll Medical Corporation Cardiac resuscitation methods and kits
US20140100282A1 (en) 2012-10-10 2014-04-10 Patrick S L Wong Intranasal administration of pharmaceutical agents for treatment of neurological diseases
WO2014064703A1 (en) 2012-10-28 2014-05-01 Peritech Pharma Ltd. Pharmaceutical liquid adhesive compositions for treatment of anorectal disorders
WO2014078857A1 (en) 2012-11-19 2014-05-22 Regents Of The University Of Minnesota Ergoline derivatives as dopamine receptor modulators
EP2931291B1 (en) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine
WO2014117089A1 (en) 2013-01-25 2014-07-31 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
WO2014130581A1 (en) 2013-02-20 2014-08-28 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
WO2014140925A2 (en) 2013-03-10 2014-09-18 Peritech Pharma Ltd. Topical compositions and methods of treatment of topical disorders
WO2014153099A2 (en) 2013-03-14 2014-09-25 Pulmonary Analytics Method for using exhaled breath to determine the presence of drug
US20160030408A1 (en) 2013-03-15 2016-02-04 Bhl Patent Holdings Llc Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve
CA2942638C (en) 2013-03-15 2026-03-10 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
WO2014142938A1 (en) 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
KR20210113429A (ko) 2013-03-15 2021-09-15 멜리어 파마슈티칼스 투, 엘엘씨. 시드노카브 또는 이의 약학적으로 허용되는 염을 포함하는 약학적 조성물 및 수면 장애를 치료하는 방법
WO2014176556A1 (en) 2013-04-26 2014-10-30 Express Diagnostics International, Inc. Portable testing system for detecting selected drugs or compounds in non-controlled environments
WO2014186623A2 (en) 2013-05-17 2014-11-20 Biomed Valley Discoveries Methods and compositions for the treatment of a chagas disease
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
CA2817728A1 (en) 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
MX2015016675A (es) 2013-06-04 2016-07-15 Vyome Biosciences Pvt Ltd Particulas recubiertas y composiciones que comprenden las mismas.
WO2014197753A1 (en) 2013-06-08 2014-12-11 Sedogen, Llc Method of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia
EP2818177A1 (en) 2013-06-24 2014-12-31 Celica, D.O.O. Mechanism and drug targets for reducing cell edema (neuroprotection) and cytoplasmic excitability in astrocytes in normal and pathological states
CA2916973A1 (en) 2013-07-03 2015-01-08 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
CA2917159C (en) 2013-07-08 2022-08-23 Auspex Pharmaceuticals, Inc. Dihydroxyphenyl neurotransmitter compounds, compositions and methods
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
HK1223298A1 (zh) * 2013-07-17 2017-07-28 阿拉伊姆药品公司 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US10098893B2 (en) 2013-10-03 2018-10-16 Northwestern University Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
US9474481B2 (en) * 2013-10-22 2016-10-25 Mindstrong, LLC Method and system for assessment of cognitive function based on electronic device usage
US9420970B2 (en) 2013-10-22 2016-08-23 Mindstrong, LLC Method and system for assessment of cognitive function based on mobile device usage
MX2016005477A (es) 2013-10-31 2016-08-03 Cima Labs Inc Formas de dosificacion disuasivas del abuso.
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
TW201605856A (zh) 2013-11-01 2016-02-16 艾尼納製藥公司 ５－ＨＴｃ受體促效劑
CN103535561A (zh) 2013-11-05 2014-01-29 杨剑 饲养大猪用的牧草饲料
CN103549133A (zh) 2013-11-05 2014-02-05 杨剑 有机猪牧草饲料
CN103751943B (zh) 2014-01-13 2020-10-13 湖北及安盾消防科技有限公司 一种含有含氮类有机化合物的灭火组合物
CN103773056B (zh) 2014-01-24 2015-11-18 山东大学 高脆性透明类岩石材料试件制备方法
AU2014379612A1 (en) 2014-01-24 2016-08-11 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
CA2978537C (en) 2014-03-03 2023-10-24 Demerx, Inc. Therapeutic uses of ibogaine and related compounds
US20150258114A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of substance abuse using ibogaine
US9878138B2 (en) 2014-06-03 2018-01-30 Pop Test Abuse Deterrent Technology Llc Drug device configured for wireless communication
US10202426B2 (en) 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses
US10231651B2 (en) 2014-09-25 2019-03-19 Bae Systems Information And Electronic Systems Integration Inc. Gait authentication system and method thereof
US10058253B2 (en) 2014-11-11 2018-08-28 Zenmark, Llc System, method, and article for heart rate variability monitoring
CA2979049A1 (en) 2015-03-10 2016-09-15 Eleusis Benefit Corporation, Pbc Lsd for the treatment of alzheimer's disease
AU2016237148A1 (en) 2015-03-24 2017-11-23 Kyowa Hakko Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticles
US10254298B1 (en) 2015-03-25 2019-04-09 National Technology & Engineering Solutions Of Sandia, Llc Detection of metabolites for controlled substances
WO2016161138A1 (en) * 2015-03-31 2016-10-06 Stamets Paul Edward Antiviral activity from medicinal mushrooms and their active constituents
DK3288946T3 (da) 2015-04-27 2019-11-25 Arena Pharm Inc 5-ht2c-receptoragonister og sammensætninger og anvendelsesfremgangsmåder
EP3288636A4 (en) 2015-05-01 2019-01-16 Topitech Pharma Israel Ltd. COMPOSITIONS FOR THE TREATMENT OF EPISTAXIS
WO2016187277A1 (en) 2015-05-19 2016-11-24 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
US20180147142A1 (en) 2015-05-19 2018-05-31 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
US9737759B2 (en) 2015-07-17 2017-08-22 Genesant Technologies, Inc. Automatic application-based exercise tracking system and method
CA3002525A1 (en) 2015-07-31 2017-02-09 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US9614734B1 (en) 2015-09-10 2017-04-04 Pearson Education, Inc. Mobile device session analyzer
JP2019523633A (ja) * 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
WO2018035477A1 (en) 2016-08-19 2018-02-22 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US10596378B2 (en) 2016-10-18 2020-03-24 Joseph Rustick Method for treatment of depression using synaptic pathway training
US20180195455A1 (en) 2017-01-12 2018-07-12 GM Global Technology Operations LLC Engine combustion phasing control during transient state
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
EP3576755A4 (en) 2017-02-02 2020-12-02 McMaster University BICARBONATE AS A POTENTIALIZER OF ANTIMICROBIAL AGENTS
WO2018145219A1 (es) 2017-02-09 2018-08-16 Serani Mostazal Jorge Composición farmaceutica para la prevención y tratamiento de las adicciones a traves de un contracondicionamiento aversivo
CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
CN108619214A (zh) 2017-03-15 2018-10-09 王慎君 一种治疗肿瘤的药物
NZ757591A (en) 2017-03-30 2026-03-27 Ojai Energetics Pbc Methods and compositions for enhancing health
AU2017408099A1 (en) 2017-04-07 2019-11-07 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US20190246591A1 (en) 2017-05-31 2019-08-15 Insectergy, Llc Insect and cannabis production systems and methods
US20180343812A1 (en) 2017-05-31 2018-12-06 Insectergy, Llc Cannabis farming systems and methods
EP3629899A4 (en) 2017-06-02 2021-04-21 Northwestern University Thin, soft, skin-mounted microfluidic networks for detection and analysis of targets of interest in sweat
CN107252080A (zh) 2017-07-12 2017-10-17 沈建国 一种麻菇酱油的配方
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3698260A4 (en) 2017-10-19 2021-08-04 Eleusis Health Solutions US, Inc. METHODS AND SYSTEMS FOR INCREASING THE SAFETY OF AWARENESS-ENHANCING DRUG THERAPIES
MA50786A (fr) 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
WO2019099745A1 (en) 2017-11-16 2019-05-23 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
US10703325B2 (en) 2017-11-27 2020-07-07 Autoliv Asp, Inc. Multi-chambered side airbag assemblies
AU2018381331A1 (en) 2017-12-04 2020-07-23 Victoria Cogger Compositions and methods for modulating liver endothelial cell fenestrations
FI128750B (en) 2017-12-21 2020-11-30 Helsingin Yliopisto Methods for determining the therapeutic effect of fast-acting antidepressants and related individual antidepressant therapy
US20190224277A1 (en) 2018-01-22 2019-07-25 CyPhi LLC Bio-mimetic formulation
WO2019161050A1 (en) 2018-02-18 2019-08-22 Akili Interactive Labs, Inc. Cognitive platform including computerized elements coupled with a therapy for mood disorder
CN120555529A (zh) 2018-03-08 2025-08-29 指南针探路者有限公司 生产色胺的方法
FI129102B (en) 2018-03-19 2021-07-15 Teknologian Tutkimuskeskus Vtt Oy Heterological production of psilosybin
AU2019262197B2 (en) 2018-05-04 2024-12-19 Perception Neuroscience, Inc. Methods of treating substance abuse
CA3148256A1 (en) 2018-06-21 2019-12-26 Robert John Petcavich Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
EP3829640A4 (en) 2018-08-01 2022-05-25 McMaster University Methods for inhibiting microbe growth
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
US11337937B2 (en) * 2018-08-27 2022-05-24 ReJoy TARR receptor agonists for sexual dysfunction
WO2020053196A1 (en) 2018-09-10 2020-03-19 Universität Basel Method for the biocatalytic alkylation of a substrate
EP3906081A4 (en) 2019-01-04 2022-10-05 Apollo Neuroscience, Inc. SYSTEMS AND METHODS OF WAVE GENERATION FOR TRANSCUTANEOUS VIBRATIONS
AU2020215150B8 (en) 2019-01-30 2025-07-03 Diamond Therapeutics Inc. Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
US20210015738A1 (en) 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US11766445B2 (en) 2019-07-18 2023-09-26 Concept Matrix Solutions Oral soft gel capsule containing psychedelic compound
EP4009026B1 (en) 2020-12-02 2024-09-18 Volvo Truck Corporation An air-actuated vehicle system and a method of detecting leakage in an air-actuated vehicle system
EP4312995A1 (en) 2021-03-30 2024-02-07 COMPASS Pathfinder Limited Psilocybin compositions, methods of making and methods of using the same
MX2024005632A (es) 2021-11-09 2024-07-29 Compass Pathfinder Ltd Tratamiento de la depresion resistente al tratamiento con psilocibina.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210121125A1 (en) * 2018-07-13 2021-04-29 Pst Inc. Apparatus for estimating mental/neurological disease
US12029579B2 (en) * 2018-07-13 2024-07-09 Pst Inc. Apparatus for estimating mental/neurological disease

Also Published As

Publication number Publication date
JP2025036703A (ja) 2025-03-14
US20250302851A1 (en) 2025-10-02
CN113993522A (zh) 2022-01-28
AU2020258086A1 (en) 2021-11-11
US20240252521A1 (en) 2024-08-01
WO2020212948A1 (en) 2020-10-22
KR20220009955A (ko) 2022-01-25
AU2020259406B2 (en) 2026-04-09
WO2020212951A1 (en) 2020-10-22
US12377112B2 (en) 2025-08-05
JP2025039633A (ja) 2025-03-21
WO2020212952A1 (en) 2020-10-22
CN113993523A (zh) 2022-01-28
US12447164B2 (en) 2025-10-21
CA3138094A1 (en) 2020-10-22
US20230124137A1 (en) 2023-04-20
US20230000883A1 (en) 2023-01-05
JP2022529476A (ja) 2022-06-22
AU2020257625B2 (en) 2026-04-09
US20230023092A1 (en) 2023-01-26
JP2025036702A (ja) 2025-03-14
US11865126B2 (en) 2024-01-09
JP2022529781A (ja) 2022-06-24
US20250367223A1 (en) 2025-12-04
TW202103699A (zh) 2021-02-01
AU2020259406A1 (en) 2021-11-04
US12433904B2 (en) 2025-10-07
KR20220008824A (ko) 2022-01-21
CA3138100A1 (en) 2020-10-22
EP3955919A1 (en) 2022-02-23
AU2020257625A1 (en) 2021-11-04
CN114206349A (zh) 2022-03-18
US20230330117A1 (en) 2023-10-19
JP2022529353A (ja) 2022-06-21
US20220169668A1 (en) 2022-06-02
EP3955918A1 (en) 2022-02-23
US11564935B2 (en) 2023-01-31
US20220088041A1 (en) 2022-03-24
CA3138008A1 (en) 2020-10-22
AU2020258086B2 (en) 2026-03-05
US11738035B2 (en) 2023-08-29
EP3955936A1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
US20250302851A1 (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
CA3240774A1 (en) Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression
US12611418B2 (en) Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
HK40068315A (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
HK40068314A (en) Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000